AUGUST 2008: New England Journal of Medicine publishes VISTA study showing VELCADE
® (bortezomib) for Injection improves survival of patients with multiple myeloma (MM)
JUNE 2008: FDA approves VELCADE for patients with previously untreated MM*
OCTOBER 2007: FDA expands VELCADE label to include use in patients with impaired kidney function, including those on dialysis
APRIL 2007: Discovery of biomarkers predictive of response to VELCADE in MM patients, highlighting applicability of genomic research to personalized medicine
DECEMBER 2006: FDA approves VELCADE for use in patients with relapsed or refractory mantle cell lymphoma
MARCH 2005: FDA approves using VELCADE in patients with MM after one therapy
JUNE 2005: NEJM publishes two studies: VELCADE in MM and MLN0002 in ulcerative colitis
APRIL 2004: EMEA grants approval to market VELCADE in Europe for treating patients with relapsed/refractory MM
MAY 2003: First FDA approval of VELCADE for treating patients with relapsed/refractory MM
